Product and licensing enquires:
Mark Court or Sophie Cowles – Buchanan
+44 (0) 20 7466 5000 or email: email@example.com
Please note that ReNeuron receives a large number of enquiries from interested parties regarding its technologies, therapeutic programmes and business operations. Whilst the Company will try to answer as many queries as it can, it has limited resources with which to do so and unfortunately may not be able to respond in all cases.
ReNeuron Group plc Head Office and Laboratories
Pencoed Business Park,
Telephone: +44 (0) 203 819 8400
ReNeuron regrets that it cannot advise or deal directly with individual patients or their physicians, relatives or friends concerning those patients’ medical conditions and the suitability of ReNeuron’s prospective stem cell therapies for treating them.
Further information including relevant contact details, may be found on clinicaltrials.gov, a registry of clinical trials providing patients, family members, and members of the public free and easy access to information on clinical studies for a wide range of diseases and conditions, regarding:
PISCES Phase I clinical trial investigating safety in disabled stroke patients (NCT01151124), please click here
PISCES Phase II clinical trial investigating efficacy in upper arm paralysis post-stroke (NCT02117635), please click here
OSIS (Observational Study in Ischaemic Stroke) non-interventional study of stroke patients (NCT01859572), please click here
Phase I clinical trial investigating safety in patients with lower limb ischaemia (NCT01916369), please click here
Phase I/II clinical trial investigating the Safety and Tolerability of Human Retinal Progenitor Cells (hRPC) in Patients with Retinitis Pigmentosa (RP) (NCT02464436) please click here